key: cord-0919352-wp8awegu authors: Duarte, R. A.; Roldao, M.; Figueiredo, C.; Luz, I.; Ferrer, F.; Goncalves, H.; Sofia, F.; Lopes, K. title: Humoral Response to BNT162b2 mRNA Covid19 Vaccine in Peritoneal and Hemodialysis Patients: a Comparative Study date: 2021-06-15 journal: nan DOI: 10.1101/2021.06.14.21258113 sha: 0ce2c8650ddd407e1a6aab43650552c4bc93f665 doc_id: 919352 cord_uid: wp8awegu Introduction Generalized immunization against COVID19 has become the cornerstone in prevention of associated severe acute respiratory syndrome. Maintenance dialysis patients (MDP) are at higher risk of both exposure and mortality from the disease. Efficacy and security of BNT162b2 vaccine is well documented for the general population, but not in MDP, particularly in peritoneal dialysis (PD) patients. This study aims to compare humoral response between HD and PD patients. Materials and Methods Observational prospective study including MDP on HD or PD program from a Portuguese middle-sized Nephrology Center, who received BNT162b2. Specific anti-Spike IgG was measured as arbitrary units per milliliter (AU/mL) on two separate occasions: 3 weeks after the first dose and 3 weeks after the second. The two modality groups were compared both for absolute value and number of non-responders (NR) after both inoculations. Demographic data was also obtained and compared. Results Of 73 patients enrolled, 67 were eligible for the final study: 42 HD and 25 PD patients. PD group developed significantly higher antibody titers both after first (Med 5.44 vs 0.99; p<0.01) and second dose (Med 170.43 vs 65.81; p<0.01). HD status was associated with non-responding after the first dose (Phi=0.383; p<0.01), but not after the second one (p=0.08). Age, Charlson Comorbidity Index and dialysis vintage were lower in the PD group (p<0.01; p=0.02; p<0.01, respectively). Conclusion This study demonstrated a better humoral response to immunization with BNT162b2 in PD patients, when comparing to HD patients, after both inoculations. Both groups showed substantial humoral response after just one dose of the vaccine. Older age and higher comorbidity burden may explain the relative immunogenicity deficit, probably in a superior degree comparing with age matched healthy population. Generalized immunization against COVID19 has become the cornerstone in prevention of severe acute respiratory syndrome associated with this pandemic. Maintenance dialysis patients (MDP) are at higher risk of both exposure and mortality from the disease. Efficacy and security of BNT162b2 vaccine is well documented for the general population, but not in MDP, particularly in peritoneal dialysis (PD) patients. This study aims to compare humoral response between hemodialysis (HD) and PD patients. Observational prospective study including MDP on HD or PD program from a Portuguese middle-sized Nephrology Center, who received BNT162b2 vaccine. Specific anti-Spike IgG was measured as arbitrary units per milliliter (AU/mL) on two separate occasions: 3 weeks after the first dose and 3 weeks after the second. The two modality groups were compared both for absolute value and number of non-responders (NR) after both inoculations. Demographic data was also compared. Of 73 patients enrolled, 67 were eligible for the final study: 42 HD and 25 PD patients. PD group developed significantly higher antibody titers in both inoculations: first dose with Med 5.44 vs 0.99 (p<0.01) and second dose with Med 170.43 vs 65.81 (p<0.01). HD status was associated with NR after the first dose (Phi=0.383; p<0.01), but not after the second (p=0.08). Age, Charlson comorbidity index and dialysis vintage were lower in the PD group (p<0.01; p=0.02; p<0.01, respectively). This study demonstrated a better humoral response to immunization with BNT162b2 in PD patients, when compared to HD patients, after each of the two recommended inoculations. Both groups showed substantial humoral response after just one dose of the vaccine. Older age and higher comorbidity burden may explain the relative immunogenicity deficit, probably in a superior degree comparing with age matched healthy population. Worldwide vaccination against coronavirus 2019 (COVID19) has become the cornerstone in prevention of Severe acute respiratory syndrome Coronavirus 2 (Sars-CoV-2) associated with this pandemic. Several vaccines with different acting mechanism have been developed, namely BNT162b2 (Pfizer BioNTech) 1 The efficacy studies for COVID19 vaccines described above did not include MDP. Humoral response to BNT162b2 in HD patients has been a target in multiple studies 11 , revealing lower titers compared to general population, however, there is still no data on PD patients. Age has also been suggested as a risk factor for worse humoral response 11 . This study aims to compare humoral response to the BNT 162b2 in our Nephrology center between PD and HD patients. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.14.21258113 doi: medRxiv preprint The study design consisted of an observational prospective study. It included a group of forty-six HD and twenty-seven PD patients who were scheduled to receive two doses of BNT 162b2 in a three-week interval, in accordance with pharmaceutical guidelines for its administration, between February and March 2021. The assessment of humoral vaccination response was done as part of the internal policy of the center's contingency protocol and informed consent of each patient was obtained regarding the use and access to these analytical results, as well as the remaining and sociodemographic information for scientific research. Blood collection and analysis was made at two distinct phases: 1) Three weeks after the inoculation of the first dose and 2) Three weeks after the second dose. Because the recommended dosing interval is three weeks, the first collection was therefore coincidentally performed with the second dose administration. Humoral response as IgG anti-Spike for COVID19 was measured in addition to IgM both for anti-Spike and anti-Nucleocapside for tracking possible contacts, even if asymptomatic. Titers were measured as arbitrary units per milliliter (AU/mL) using chemiluminescence. Response was considered significant for titers superior to 1 AU/mL. Inclusion criteria included capacity to understand and provide informed consent and who did not show a significant increase in specific IgM anti-N for COVID19 during follow-up. We hypothesized that both humoral response, as measured by IgG anti-Spike, and response rate would be higher in the PD group. As primary endpoints we established the comparison between the median of achieved titers to both the first and second dose and between rate of non-responders (NR) for each modality. Secondary endpoints focused on comparison of demographic data including age, sex, diabetes, Charlson comorbidity index (CCI) and dialysis vintage. Statistical analysis was carried out using Microsoft Excel 2016 and IBM SPSS Statistics 25 software. Study variables, divided in demographic and humoral, are summarized in table 1. Descriptive analysis was performed using frequencies and percentages for categorical All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Demographic data, anti-spike IgG levels and NR rate were compared between both modality groups. Differences in continuous variables between groups were analyzed with Student's t-test for means (parametric) and Mann-Whitney U test for medians (nonparametric). The response rate was also analyzed between modalities using Fisher's exact test and Phi correlation coefficient. Pearson and Spearman correlation tests between antibody levels and continuous variables were also performed, if normal distributed or not, respectively. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.14.21258113 doi: medRxiv preprint Of the forty-six HD patients enrolled, forty-two were eligible for the study: 1) two patients discontinued dialysis before the administration of the second dose; 2) one patient died from an unrelated cause and 3) despite asymptomatic one patient showed a significant increase in IgM titer raising the possibility of contact with the virus. Similarly, two patients from the PD group showed significant increase in specific IgM and were considered to have asymptomatic infection, resulting in twenty-five PD patients being enrolled into the statistical analysis, a total of sixty-seven MDP. Demographic data is summarized in an outcome that was observed in 6 patients from the HD group. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.14.21258113 doi: medRxiv preprint Overall, humoral response to BNT162b2 evaluated by IgG anti-Spike titers is significant in MDP with only 9% of the total sample failing to achieve measurable response, all from the HD group. The fact that the difference in NR for the second dose was not statistically different, even though all identified NR were from the HD group, suggests insufficient sample size. Regarding the method to assess antibody immune response (in arbitrary units), it is important to highlight that its laboratory dependence does not allow for external comparison. Our study support that PD patients achieve a significant higher humoral response when compared to the HD counterpart. The analysis of demographic data favors PD patients as a younger population, with less dialysis vintage and less comorbidity burden (as evaluated by CCI) when compared to HD patients. These differences are expected given the nature, requirements and indications of each modality. Multiple studies have found advanced age to be an independent risk factor for low humoral response to BNT162b2 and it can play a role in our study results. Approximately half of the patients in the HD group were diabetics, whereas that number dropped to a fifth in the PD group, without a statistically significant difference. It is well known. It is well known that diabetes is associated with an overall immune response dysfunction. However, larger studies may be necessary to establish the role of diabetes in antibody immune response between dialysis modalities. It is worth noting that, during the follow up no patient developed clinically significant COVID-19 disease or was diagnosed with it via nasopharyngeal swab. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.14.21258113 doi: medRxiv preprint This study suggests that humoral response in MDP is significantly different for BNT 162b2 vaccination depending on modality, with PD patients showing higher titers after both first and second doses when compared to their HD counterpart. Demographic differences between the two groups must be considered, namely disparities in age and comorbidity burden. The influence of said factors in overall humoral response is unknown. Additional studies are, therefore, required to further explore immunogenicity factors and in dialysis population. The identification and signalization of higher risk subgroups in MDP for insufficient or no response to vaccination is essential, providing institutions an opportunity to develop and establish protective and follow-up protocols in this pandemic. To the best of our knowledge, this is the first study evaluating humoral response to BNT162b2 vaccine in PD patients and also comparing them with their HD counterpart. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.14.21258113 doi: medRxiv preprint Safety and Efficacy of the BNT162b2 mRNA Covid-19 Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a singleblind, randomised, controlled, phase 2/3 trial Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States Presentation and Outcomes of Patients with ESKD and COVID-19 Hepatitis B Vaccine in Patients Receiving Hemodialysis Long-Term Immunogenicity and Efficacy of Hepatitis B Vaccine in Hemodialysis Patients Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity